|By Marketwired .||
|May 8, 2014 08:30 AM EDT|
VALENCIA, SPAIN -- (Marketwired) -- 05/08/14 -- Zenosense, Inc. (OTCQB: ZENO) (the "Company"), a healthcare technology company focused on developing and marketing a device for use in hospitals and other healthcare settings to detect the Methicillin-resistant Staphylococcus aureus (MRSA) "Super-Bug," is pleased to announce that the Company has extended its agreement with the Sgenia Group ("Sgenia") to include cancer sensory devices.
Under the terms of the extension, Zenosense has the optional right to fund the development of prospective cancer sensory devices that may be based on the Sgenia technology. Subject to providing funding, the Company will have the right to manufacture, market and sell the resulting devices(s), if developed.
The Company believes the sensory technology and algorithmic processing in development for MRSA detection could, if successful, be applied to certain cancer sensory devices. Some cancers, such as lung and colon, produce volatile organic compounds ("VOCs") in an individual's breath in a similar way to patients infected with MRSA. Should the cancer specific pattern of VOCs be identified, the Company believes that a relatively straightforward modification of a successful MRSA detection technology may enable it to produce a similar device for the detection of certain cancers.
Zenosense believes there could be substantial demand for a relatively low cost, rapid detection device for these types of cancer. Such a device could allow for much wider screening and the ability to detect, for example, lung cancer at a much earlier stage and on a mass scale. Currently lung cancer is typically caught at a late stage when fewer than 25% of cases can be cured; however, in Stage I there is a 70% cure rate.
About Zenosense, Inc.
Zenosense, Inc. is a detection device development company based in Valencia, Spain. Its mission is develop, market and sell an effective MRSA detector, by way of licensed-in technology, for sale to healthcare providers for use in clinical settings. The Company believes there is enormous latent demand for a cost-effective MRSA detector, driven by the costs associated with the late detection of MRSA, and that it has identified a valuable new market segment for a wearable detection device. The development and exclusive license agreement also includes cancer sensory devices. Find out more at www.zenosense.net.
Statements in this news release that are not statements of historical fact are forward-looking statements, which are subject to certain risks and uncertainties. Forward-looking statements can often be identified by words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of factors that may or may not be foreseeable or within the reasonable control of the Company. Readers are cautioned not to place undue reliance on such forward-looking statements. Additional information on risks and other factors that may affect the business and financial results of the Company can be found in filings of the Company with the U.S. Securities and Exchange Commission, including without limitation the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2013 filed on filed on March 26, 2014, and in Company reports filed subsequently thereto. Except as otherwise required by law, the Company disclaims any obligations or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this news release to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
SYS-CON Events announced today that Isomorphic Software will exhibit at DevOps Summit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Isomorphic Software provides the SmartClient HTML5/AJAX platform, the most advanced technology for building rich, cutting-edge enterprise web applications for desktop and mobile. SmartClient combines the productivity and performance of traditional desktop software with the simp...
Aug. 29, 2016 03:00 AM EDT Reads: 2,394
Aug. 29, 2016 02:15 AM EDT Reads: 1,817
Aug. 29, 2016 02:15 AM EDT Reads: 2,198
Aug. 29, 2016 01:45 AM EDT Reads: 2,174
Aug. 29, 2016 01:15 AM EDT Reads: 3,008
Aug. 29, 2016 01:00 AM EDT Reads: 2,222
Aug. 29, 2016 12:00 AM EDT Reads: 1,889
Aug. 28, 2016 11:15 PM EDT Reads: 2,150
Aug. 28, 2016 10:30 PM EDT Reads: 4,060
Aug. 28, 2016 08:30 PM EDT Reads: 1,844
Aug. 28, 2016 08:15 PM EDT Reads: 1,957
Aug. 28, 2016 07:30 PM EDT Reads: 714
Aug. 28, 2016 06:30 PM EDT Reads: 1,635
Aug. 28, 2016 06:00 PM EDT Reads: 1,948
Aug. 28, 2016 05:30 PM EDT Reads: 788